Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions
Tóm tắt
To evaluate the local control (LC), progression free survival (PFS), out-field PFS, overall survival (OS), toxicity and failure predictors of SRT in a series of various sites oligometastatic CRC patients. Patients with oligometastatic CRC disease were analyzed retrospectively. The SRT prescribed dose was dependent on the lesion volume and its location. 102 consecutive oligometastatic CRC patients (150 lesions) were included. They underwent SRT between 2012 and 2015. Median prescription dose was 45 Gy (median dose/fraction was 15 Gy/3 fractions biological equivalent dose (BED10) 112.5 Gy). Median follow-up was 11.4 months. No patients experienced G3 and G4 toxicity. No progression was found in 82% (radiological response at 3 months) and 85% (best radiological response) out of 150 evaluable lesions. At 1 and 2 years: LC was 70% and 55%; OS was 90% and 90%; PFS was 37% and 27%; out-field PFS was 37% and 23% respectively. Progressive disease was correlated with BED10 (better LC when BED10 was ≥ 75 Gy (p < 0.0001)). In multivariate analysis, LC was higher in lesions with a Plpnning target volume (PTV) volume < 42 cm3 and BED10 ≥ 75 Gy. Patients with Karnofsky performance status < 90 showed higher out-field progression. SRT is an effective treatment for patients with oligometastases from CRC. Its low treatment-associated morbidity and acceptable LC make of SRT an option not only in selected cases. Further studies should be focused to clarify which patient subgroup will benefit most from this treatment modality and to define the optimal dose to improve LC while maintaining low toxicity profile.
Tài liệu tham khảo
Sahgal A, Roberge D, Schellenberg D et al (2012) The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol) 24:629–639
Palma DA, Louie AV, Rodrigues GB (2015) New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res 21:5198–5204
Rusthoven K, Kavanagh B, Burri S et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579–1584
Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591
Siva S, Pham D, Kron T et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120:623–630
Wang XS, Rhines LD, Shiu AS et al (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13:395–402
Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830
Franceschini D, Cozzi L, De Rose F et al (2017) Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. J Cancer Res Clin Oncol 143:1293–1299
Wiechselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382
Alongi F, Arcangeli S, Filippi AR et al (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17:1100–1107
Wang CC, Li J (2012) An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 18:25–33
Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900–909
Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715–22. Discussion 722–724
Giantonio BJ, Levy DE, O’dwyer PJ, Eastern Cooperative Oncology Group et al (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17:1399–1403
Kavanagh BD, McGarry RC, Timmerman RD (2006) Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16:77–84
Primrose JN (2010) Surgery for colorectal liver metastases. Br J Cancer 102(9):1313–1318
Kanemitsu Y, Takakura Y, Miyata Y et al (2010) Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer. Colorectal Dis 12:e68–e75
Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on stereotactic radiotherapy. Strahlenther Onkol 190:872–881
Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342
McDermott S, Gervais DA (2013) Radiofrequency ablation of liver tumors. Semin Intervent Radiol 30(1):49–55
Ruers T, Van Coevorden F, Punt CJ, European Organisation for Research and Trea tment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG) et al (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx015
Ahmed K, Caudell JJ, El-Haddad G et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95(5):1399–1404
Klement RJ, Guckenberger M, Alheid H et al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease-influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123(2):227–233
Kobiela J, Spychalski P, Marvaso G et al (2018) Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol 129:91–101
Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830
Ricotti R, Seregni M, Ciardo D et al (2018) Evaluation of target coverage and margins adequacy during CyberKnife lung optimized treatment. Med Phys 45(4):1360–1368
Bradley JD, Nofal AN, El Naqa IM et al (2006) Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. Radiother Oncol 81(3):264–268
Timmerman RD (2008) An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 18:215–222
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
CTCAE 4.03. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Available from http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 20 March 2016. Last updated 2013
Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897
Lazzari R, Ronchi S, Gandini S et al (2018) Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys 101(3):650–660
Jereczek-Fossa BA, Fanetti G, Fodor C et al (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15(4):e623–e632
Orecchia R, Surgo A, Muto M et al (2016) VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience 10:677
Adam R, Wicherts D, De Haas R et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clinl Oncol 27:1829–1835
Lagerwaard FJ, Aaronson NK, Gundy CM et al (2012) Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 7(7):1148–5437
Holmes OE, Gratton J, Szanto J et al (2018) Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT). Radiosurg SBRT 5(3):217–227
Comito T, Cozzi L, Clerici E et al (2014) Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 14:619
Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069
Joo JH, Park JH, Kim JC et al (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99(4):876–883
Andratschke N, Alheid H, Allgäuer M et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283
Chahine G, Ibrahim T, Felefly T et al (2018) Colorectal cancer and brain metastases: an aggressive disease with a different response to treatment. Tumori. https://doi.org/10.1177/0300891618765541
Ahmed KA, Fulp WJ, Berglund AE et al (2015) Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys 92(4):837–842
Ricco A, Davis J, Rate W et al (2017) Lung metastases treated with stereotacticbody radiotherapy: the RSSearch® patientRegistry’s experience. Radiat Oncol 12(1):35
Lee M, Kim J, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591
Bae SH, Kim MS, Cho CK et al (2012) High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 106:138–143
Qiu H, Katz AW, Chowdhry AK et al (2018) Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol 41(1):53–58